Matt Abernethy, Chief Financial Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 14,100 shares at $150.38 ($2.1M) on 2024-08-13, disclosed to the SEC on 2024-08-15.
Scheduled sale ($2.1M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| NBIX | SELL | 2025-02-12 | $232K | — | Filing → |
| NBIX | SELL | 2025-02-04 | $392K | — | Filing → |
| NBIX | SELL | 2024-07-18 | $135K | — | Filing → |